Bevacizumab, sorafenib, sunitinib and temsirolimus have been approved for use in patients with advanced solid cancers. Many other drugs with activity in preclinical models, however, have failed to show efficacy in clinical trials. The authors of this Review describe the studies that led to the approval of these antiangiogenic agents, discuss the potential value of biomarkers of angiogenesis, and provide rationale for future developments.
- Cristiana Sessa
- Aymeric Guibal
- Curzio Rüegg
